PNH Overview Epidemiology: Prevalence and incidence Clinical presentation: Physical exam, laboratory evidence Differential diagnosis, diagnosis, classification Common presenting symptoms Risks of short- and long-term complications Prognosis

Treatment Currently available therapy Complement inhibitors: Available agents; mechanism of action; dosing and formulations; evidence HSCT: When to consider Investigational therapies: Additional complement inhibitors and targets in the complement cascade; factors B and D inhibitors Supportive care Patient case(s)

 

By the end of the session the participant will be able to:

• Describe the common clinical presentation(s) of PNH.
• Describe challenges to the successful identification of patients with PNH and solutions to overcoming diagnostic barriers.
• Identify the treatment modalities presently available and emerging therapies for management of PNH and formulate a treatment plan based on patient case details.
• Compare the mechanisms of action, dose schedules, and efficacy data for novel and emerging treatment options for PNH.

ACCME Activity #201824508

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:

Carlos M. De Castro, MD, Professor of Medicine, Duke University, has received financial compensation as a speaker and / or consultant for Alexion, Apellis, Novartis and Biocryst.

Faculty DOES plan on discussing off-label uses of a commercial product.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Biocryst and Apellis.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version